A comparative study of contrast agents for endoscopic retrograde pancreatography

Jamie S Barkin, G. L. Casal, D. K. Reiner, R. I. Goldberg, R. S. Phillips, S. Kaplan

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Pancreatitis is a major cause of morbidity and mortality secondary to endoscopic retrograde pancreatography (ERP). One factor that may cause post-ERP pancreatitis is the type of contrast media utilized during the procedure. The purpose of this prospective, double-blind, randomized study was to evaluate the effects of three contrast agents of differing osmolality and ionicity on changes between pre- and post-ERP chemical changes in serum amylase and lipase and development of clinical symptoms of acute pancreatitis. Our study of 53 patients showed that those who received Omnipaque a non-ionic, relatively iso-osmolar contrast agent, had a significantly lower serum amylase (p = 0.0038) and serum lipase (p = 0.0002) in post-ERP serological markers, compared with patients who received the ionic agents, Hypaque meglumine 60% or Hexabrix. In addition, the development of clinical symptoms of pancreatitis was less in patients who received Omnipaque than in those who received Hexabrix or Hypaque (1 vs. 3 vs. 4). No significant difference was found between patients who received ionic agents. No patient who received Omnipaque needed hospitalization, whereas one (6%) patient who received Hexabrix was hospitalized compared to three (20%) hospitalized patients who received Hypaque. When the initial cost and cost of hospitalization were compared, the non-ionic contrast medium was also found to be more cost-effective for the patient. In summary, the risk of post-ERP acute pancreatitis was significantly lower for patients who received the non-ionic contrast agent than for those who received the ionic agents.

Original languageEnglish
Pages (from-to)1437-1441
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume86
Issue number10
StatePublished - Jan 1 1991

Fingerprint

Contrast Media
Pancreatitis
Ioxaglic Acid
Iohexol
Diatrizoate
Amylases
Lipase
Costs and Cost Analysis
Hospitalization
Serum
Meglumine
Double-Blind Method
Osmolar Concentration
Morbidity
Mortality

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Barkin, J. S., Casal, G. L., Reiner, D. K., Goldberg, R. I., Phillips, R. S., & Kaplan, S. (1991). A comparative study of contrast agents for endoscopic retrograde pancreatography. American Journal of Gastroenterology, 86(10), 1437-1441.

A comparative study of contrast agents for endoscopic retrograde pancreatography. / Barkin, Jamie S; Casal, G. L.; Reiner, D. K.; Goldberg, R. I.; Phillips, R. S.; Kaplan, S.

In: American Journal of Gastroenterology, Vol. 86, No. 10, 01.01.1991, p. 1437-1441.

Research output: Contribution to journalArticle

Barkin, JS, Casal, GL, Reiner, DK, Goldberg, RI, Phillips, RS & Kaplan, S 1991, 'A comparative study of contrast agents for endoscopic retrograde pancreatography', American Journal of Gastroenterology, vol. 86, no. 10, pp. 1437-1441.
Barkin JS, Casal GL, Reiner DK, Goldberg RI, Phillips RS, Kaplan S. A comparative study of contrast agents for endoscopic retrograde pancreatography. American Journal of Gastroenterology. 1991 Jan 1;86(10):1437-1441.
Barkin, Jamie S ; Casal, G. L. ; Reiner, D. K. ; Goldberg, R. I. ; Phillips, R. S. ; Kaplan, S. / A comparative study of contrast agents for endoscopic retrograde pancreatography. In: American Journal of Gastroenterology. 1991 ; Vol. 86, No. 10. pp. 1437-1441.
@article{82ecfca8771646bcafc405f8beb7025d,
title = "A comparative study of contrast agents for endoscopic retrograde pancreatography",
abstract = "Pancreatitis is a major cause of morbidity and mortality secondary to endoscopic retrograde pancreatography (ERP). One factor that may cause post-ERP pancreatitis is the type of contrast media utilized during the procedure. The purpose of this prospective, double-blind, randomized study was to evaluate the effects of three contrast agents of differing osmolality and ionicity on changes between pre- and post-ERP chemical changes in serum amylase and lipase and development of clinical symptoms of acute pancreatitis. Our study of 53 patients showed that those who received Omnipaque a non-ionic, relatively iso-osmolar contrast agent, had a significantly lower serum amylase (p = 0.0038) and serum lipase (p = 0.0002) in post-ERP serological markers, compared with patients who received the ionic agents, Hypaque meglumine 60{\%} or Hexabrix. In addition, the development of clinical symptoms of pancreatitis was less in patients who received Omnipaque than in those who received Hexabrix or Hypaque (1 vs. 3 vs. 4). No significant difference was found between patients who received ionic agents. No patient who received Omnipaque needed hospitalization, whereas one (6{\%}) patient who received Hexabrix was hospitalized compared to three (20{\%}) hospitalized patients who received Hypaque. When the initial cost and cost of hospitalization were compared, the non-ionic contrast medium was also found to be more cost-effective for the patient. In summary, the risk of post-ERP acute pancreatitis was significantly lower for patients who received the non-ionic contrast agent than for those who received the ionic agents.",
author = "Barkin, {Jamie S} and Casal, {G. L.} and Reiner, {D. K.} and Goldberg, {R. I.} and Phillips, {R. S.} and S. Kaplan",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "86",
pages = "1437--1441",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - A comparative study of contrast agents for endoscopic retrograde pancreatography

AU - Barkin, Jamie S

AU - Casal, G. L.

AU - Reiner, D. K.

AU - Goldberg, R. I.

AU - Phillips, R. S.

AU - Kaplan, S.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Pancreatitis is a major cause of morbidity and mortality secondary to endoscopic retrograde pancreatography (ERP). One factor that may cause post-ERP pancreatitis is the type of contrast media utilized during the procedure. The purpose of this prospective, double-blind, randomized study was to evaluate the effects of three contrast agents of differing osmolality and ionicity on changes between pre- and post-ERP chemical changes in serum amylase and lipase and development of clinical symptoms of acute pancreatitis. Our study of 53 patients showed that those who received Omnipaque a non-ionic, relatively iso-osmolar contrast agent, had a significantly lower serum amylase (p = 0.0038) and serum lipase (p = 0.0002) in post-ERP serological markers, compared with patients who received the ionic agents, Hypaque meglumine 60% or Hexabrix. In addition, the development of clinical symptoms of pancreatitis was less in patients who received Omnipaque than in those who received Hexabrix or Hypaque (1 vs. 3 vs. 4). No significant difference was found between patients who received ionic agents. No patient who received Omnipaque needed hospitalization, whereas one (6%) patient who received Hexabrix was hospitalized compared to three (20%) hospitalized patients who received Hypaque. When the initial cost and cost of hospitalization were compared, the non-ionic contrast medium was also found to be more cost-effective for the patient. In summary, the risk of post-ERP acute pancreatitis was significantly lower for patients who received the non-ionic contrast agent than for those who received the ionic agents.

AB - Pancreatitis is a major cause of morbidity and mortality secondary to endoscopic retrograde pancreatography (ERP). One factor that may cause post-ERP pancreatitis is the type of contrast media utilized during the procedure. The purpose of this prospective, double-blind, randomized study was to evaluate the effects of three contrast agents of differing osmolality and ionicity on changes between pre- and post-ERP chemical changes in serum amylase and lipase and development of clinical symptoms of acute pancreatitis. Our study of 53 patients showed that those who received Omnipaque a non-ionic, relatively iso-osmolar contrast agent, had a significantly lower serum amylase (p = 0.0038) and serum lipase (p = 0.0002) in post-ERP serological markers, compared with patients who received the ionic agents, Hypaque meglumine 60% or Hexabrix. In addition, the development of clinical symptoms of pancreatitis was less in patients who received Omnipaque than in those who received Hexabrix or Hypaque (1 vs. 3 vs. 4). No significant difference was found between patients who received ionic agents. No patient who received Omnipaque needed hospitalization, whereas one (6%) patient who received Hexabrix was hospitalized compared to three (20%) hospitalized patients who received Hypaque. When the initial cost and cost of hospitalization were compared, the non-ionic contrast medium was also found to be more cost-effective for the patient. In summary, the risk of post-ERP acute pancreatitis was significantly lower for patients who received the non-ionic contrast agent than for those who received the ionic agents.

UR - http://www.scopus.com/inward/record.url?scp=0025931335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025931335&partnerID=8YFLogxK

M3 - Article

C2 - 1928034

AN - SCOPUS:0025931335

VL - 86

SP - 1437

EP - 1441

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -